These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9288771)

  • 41. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
    Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
    Wilkens EP; Freije D; Xu J; Nusskern DR; Suzuki H; Isaacs SD; Wiley K; Bujnovsky P; Meyers DA; Walsh PC; Isaacs WB
    Prostate; 1999 Jun; 39(4):280-4. PubMed ID: 10344217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRCA-associated breast cancer in young women.
    Robson M; Gilewski T; Haas B; Levin D; Borgen P; Rajan P; Hirschaut Y; Pressman P; Rosen PP; Lesser ML; Norton L; Offit K
    J Clin Oncol; 1998 May; 16(5):1642-9. PubMed ID: 9586873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
    Kotsopoulos J; Lubinski J; Moller P; Lynch HT; Singer CF; Eng C; Neuhausen SL; Karlan B; Kim-Sing C; Huzarski T; Gronwald J; McCuaig J; Senter L; Tung N; Ghadirian P; Eisen A; Gilchrist D; Blum JL; Zakalik D; Pal T; Sun P; Narod SA;
    Breast Cancer Res Treat; 2014 Feb; 143(3):579-86. PubMed ID: 24458845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
    J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women.
    Apicella C; Dowty JG; Dite GS; Jenkins MA; Senie RT; Daly MB; Andrulis IL; John EM; Buys SS; Li FP; Glendon G; Chung W; Ozcelik H; Miron A; Kotar K; Southey MC; Foulkes WD; Hopper JL
    Clin Genet; 2007 Aug; 72(2):87-97. PubMed ID: 17661812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
    Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
    J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
    Milne RL; Knight JA; John EM; Dite GS; Balbuena R; Ziogas A; Andrulis IL; West DW; Li FP; Southey MC; Giles GG; McCredie MR; Hopper JL; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):350-6. PubMed ID: 15734957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New discoveries on oral contraceptives and risk of breast cancer. International data show a moderate increase in risk].
    Persson I
    Lakartidningen; 1996 Dec; 93(50):4613-6. PubMed ID: 8999253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reproductive factors in hereditary breast cancer.
    Jernström HC; Johannsson OT; Loman N; Borg A; Olsson H
    Breast Cancer Res Treat; 1999 Dec; 58(3):295-301. PubMed ID: 10718491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    Brohet RM; Goldgar DE; Easton DF; Antoniou AC; Andrieu N; Chang-Claude J; Peock S; Eeles RA; Cook M; Chu C; Noguès C; Lasset C; Berthet P; Meijers-Heijboer H; Gerdes AM; Olsson H; Caldes T; van Leeuwen FE; Rookus MA
    J Clin Oncol; 2007 Sep; 25(25):3831-6. PubMed ID: 17635951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
    Claus EB; Schildkraut J; Iversen ES; Berry D; Parmigiani G
    J Natl Cancer Inst; 1998 Dec; 90(23):1824-9. PubMed ID: 9839523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
    Phillips KA; Nichol K; Ozcelik H; Knight J; Done SJ; Goodwin PJ; Andrulis IL
    J Natl Cancer Inst; 1999 Mar; 91(5):469-73. PubMed ID: 10070948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history.
    Hartge P; Chatterjee N; Wacholder S; Brody LC; Tucker MA; Struewing JP
    Epidemiology; 2002 May; 13(3):255-61. PubMed ID: 11964925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Should women with a family history of breast cancer avoid use of oral contraceptives?
    Ursin G; Li C; Pike MC
    Epidemiology; 2000 Sep; 11(5):615-6. PubMed ID: 10955421
    [No Abstract]   [Full Text] [Related]  

  • 57. Re: Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
    Kaufman DJ; Struewing JP
    J Natl Cancer Inst; 1999 Jul; 91(14):1250-1. PubMed ID: 10413427
    [No Abstract]   [Full Text] [Related]  

  • 58. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.
    Jernström H; Lerman C; Ghadirian P; Lynch HT; Weber B; Garber J; Daly M; Olopade OI; Foulkes WD; Warner E; Brunet JS; Narod SA
    Lancet; 1999 Nov; 354(9193):1846-50. PubMed ID: 10584720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.
    Henningson M; Johansson U; Borg A; Olsson H; Jernström H
    Mol Hum Reprod; 2007 Apr; 13(4):231-6. PubMed ID: 17307805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral contraceptives and risk of familial breast cancer.
    Heimdal K; Skovlund E; Møller P
    Cancer Detect Prev; 2002; 26(1):23-7. PubMed ID: 12088199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.